- Bora Pharmaceuticals has completed the US$122.5 million acquisition of MacroGenics’ GMP biologics manufacturing operations in Maryland and signed a long-term CDMO services agreement with MacroGenics.
- The acquisition expands Bora Biologics’ U.S. manufacturing network to 20,000 liters of single-use bioreactor capacity across two commercial manufacturing sites.
Bora Pharmaceuticals Co., Ltd. has completed the acquisition of the GMP manufacturing operations of MacroGenics, including its biologics drug substance manufacturing facility in Rockville, Maryland, and an associated warehousing center in Frederick, Maryland, for a total consideration of US$122.5 million. Following the transaction, Bora also signed a long-term CDMO services agreement with MacroGenics.
The acquisition expands Bora Biologics’ manufacturing network to 20,000 liters of single-use bioreactor drug substance capacity across commercial sites in Rockville, Maryland, and San Diego, California, as well as a development facility in Zhubei, Taiwan. According to the company, the expanded platform is intended to support biologics manufacturing from development through commercial supply.
Bora said the Rockville facility currently supports more than four commercial programs and has completed more than 120 GMP batches supplying products to markets including the United States, Europe, Japan, Canada, and the United Kingdom. Across its U.S. network, the company said it has completed five U.S. FDA inspections and one PMDA review in 2025, while the combined platform has supported more than 33 biologics and 15 biosimilars.
“This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply.”
Bobby Sheng, Chairman and CEO of Bora Group
The company said it plans to integrate its U.S. drug substance capabilities with its existing sterile drug product operations over the next 12 to 18 months, creating an end-to-end contract manufacturing platform for biologics.
